STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Matrixyl (palmitoyl pentapeptide-4)

Also known as

Palmitoyl pentapeptide-4 · Palmitoyl pentapeptide-3 (pre-2006 INCI) · Pal-KTTKS · Pal-Lys-Thr-Thr-Lys-Ser · Matrixyl · Matrixyl™ (Sederma / Croda trade name — classic) · Matrixyl 3000 (related brand line; different peptides) · Matrixyl Synthe'6 / Synthe’6 (related brand line; palmitoyl tripeptide-38) · Matrixyl Morphomics (related brand line; palmitoyl tripeptide-56 acetate) · PPP-4 · Collagen pentapeptide (community shorthand)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Local Topical Skin, hair & tissue remodeling

Local — a face/skin serum, not a whole-body shot.

What people say Classic Matrixyl is topical palmitoyl pentapeptide-4, or Pal-KTTKS. The Matrixyl brand also covers other peptide mixtures, so a front-label percentage may describe a dilute commercial complex rather than free Pal-KTTKS. Doses people talk about
Twelve-week split-face trial3 ppm (0.0003%) Pal-KTTKS topical

Moisturizer containing Pal-KTTKS versus matching vehicle in 93 women; manufacturer-affiliated authors and cosmetic endpoints.

Historic periocular study0.005% palmitoyl pentapeptide-4 topical

Applied twice daily for 28 days in a study summarized by later reviews; original lineage is partly brand-linked.

CIR reported leave-on useUp to 0.0012% Palmitoyl Pentapeptide-4 topical

Highest reported concentration in the 2022 leave-on use survey, specifically eye lotions; not a universal safety ceiling.

Consumer blend label10% combined branded Matrixyl complexes topical

The preserved product example describes Matrixyl 3000 plus Synthe'6 in an HA vehicle; it is not 10% free Pal-KTTKS.

The adverse and benefit reports concern finished multi-ingredient products. Concentration, peptide generation and vehicle must stay attached to each claim.

Half-life & effect duration

Half-life in the body
  • Topical Pal-KTTKSNo settled estimate
Felt duration people report
  • Early adverse accountPainful dryness within days
  • Appearance reportsUncertain smoothing at 5 weeks, or small changes at 6 months
Timing context & sources
How it may feel A 12-week 3 ppm split-face trial reported modest wrinkle improvement and good tolerance. Actual product reports ranged from painful dryness within days to subtle or uncertain smoothing after five weeks and only small change after six months.
Cycles people discuss Topical use is discussed as ongoing daily or twice-daily skincare across multi-week studies, not a systemic peptide cycle. Visible changes, when present, are gradual and product-dependent. Timing Topical use is generally once or twice daily after cleansing. Twice-daily routines may split peptide and retinoid between morning and evening, while strong acids or low-pH vitamin C are sometimes separated to manage irritation; these are routine conventions, not hard compatibility rules. Stacks Matrixyl products commonly sit with hyaluronic acid, niacinamide, sunscreen, retinoids or other peptides. Multi-active routines and blended Matrixyl generations make single-ingredient attribution weak. Watch for Local irritation: Mild redness, sting, dryness, or tightness — often vehicle, fragrance, preservatives, or multi-active over-stacking rather than pure Pal-KTTKS at ppm levels.
Related
GHK-CuArgireline

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

No public human systemic parent-peptide half-life was established for topical Pal-KTTKS.

The in-vitro Franz-cell experiment in the CIR review found Pal-KTTKS in hairless-mouse skin layers, with receptor-fluid signal below quantification and no quantified full-thickness permeation.

Animal in-vitro skin work cannot establish human plasma PK; local skin retention is not a systemic half-life measurement.

  • Cosmetic Ingredient Review — Pentapeptide-4 ingredient safety assessment (opens in a new tab)Use section reports 0.0012% as the highest 2022 leave-on Palmitoyl Pentapeptide-4 concentration; the toxicokinetic section summarizes an in-vitro Franz-cell study using full-thickness hairless-mouse skin samples and measuring skin retention.The inspected PDF is a 2023 scientific-literature-review stage document; reported use concentration is not a universal safety limit, and mouse skin is not human systemic PK.

Felt duration people report

Reports range from painful dryness within days to uncertain smoothing at five weeks or small change at six months; a 3 ppm trial measured benefit over 12 weeks.

Community products contained vehicles and sometimes multiple Matrixyl generations or other actives, while the controlled trial compared a defined Pal-KTTKS moisturizer with vehicle.

Self-reports lack product assays and controlled routines; the trial had manufacturer-affiliated authors, a narrow population and cosmetic rather than medical endpoints.

Other context in this card

What people say 14

  • Firmness / texture: Users and cosmetic graders report smoother texture, less makeup-catching fine lines, and modest firmness over weeks of consistent use — hydration vehicle effect is a real confound. forum
  • vs retinoids (user positioning): Framed as gentler daily anti-aging for sensitive, barrier-compromised, pregnancy-planning, or retinoid-intolerant skin — not as stronger than tretinoin for photoaging. forum
  • Matrixyl 3000 manufacturer claims (adjacency, not pure PPP-4): Sederma-style 3% Matrixyl 3000 complex twice daily ~2 months — often-cited figures include ~39% reduction deep-wrinkle surface area, ~20% main-wrinkle depth, roughness/lifting/tonicity gains; also “age gain” marketing language (~2 years in 1 month / up to ~5.5 years in 2 months). Manufacturer-sponsored; independent peer review thinner. forum
  • Matrixyl Synthe'6 manufacturer claims (adjacency): 2% active complex daily ~2 months — marketing claims of boosting six matrix components (collagen I/III/IV, fibronectin, HA, laminin-5) and wrinkle decreases especially forehead/crow’s feet (e.g. ~31% up to 100% self-report style vendor language). forum
  • Matrixyl Morphomics (adjacency): Palmitoyl tripeptide-56 acetate marketed for vertical lines (nasolabial, marionette, frown) with visible change talk around ~6 weeks. forum
  • Stack confounds: Multi-peptide + HA + niacinamide + retinoid routines make single-agent credit unreliable; “Matrixyl fixed my lines” logs often co-use SPF and other actives. forum
  • What logs rarely claim: Overnight Botox-like freeze, fat loss, systemic recovery, or acute “feel.” Slow cosmetic remodeling only. forum
  • Photoaged facial wrinkles (Robinson 2005): 12-week double-blind, placebo-controlled, split-face trial in 93 Caucasian women (35–55): moisturizer with 3 ppm pal-KTTKS vs same moisturizer without — significant improvement in wrinkles/fine lines by technical measures and expert grader image analysis; well tolerated. trial
  • Periocular profilometry (~0.005% band): Placebo-controlled double-blind work applying ~0.005% pal-KTTKS periocular twice daily for 28 days — cited decreases of ~18% fold depth, ~37% fold thickness, ~21% skin rigidity (optical profilometry); related periorbital wrinkle studies in women with moderate–distinct crow’s feet. trial
  • Longer face protocols: Four-month double-blind vehicle-controlled face application (twice daily) associated with improved skin roughness, wrinkle volume, and wrinkle depth vs vehicle in review summaries; elastin fiber density/thickness and collagen IV at the dermal–epidermal junction also discussed. trial
  • Crow’s feet RCT (Aruan et al., 2023): Double-blind randomized trial, 21 Indonesian women 26–55, 8 weeks, twice-daily periorbital cream: palmitoyl pentapeptide-4 vs acetylhexapeptide-3 (Argireline-class) vs placebo. PPP-4 described as showing better results than AHP-3 on data, photos, and self-assessment; authors call for larger samples. trial
  • Tech-neck / barcode lines: Newer cosmetic imaging work on palmitoyl pentapeptide-4 creams twice daily over ~56 days — significant decreases in tech-neck and perioral “barcode” lines by ~day 28 with continued improvement, plus collagen-index narratives vs placebo decline. Brand/cosmetic-trial context. trial
  • In-vitro ECM: Fibroblast work and reviews emphasize procollagen and matrix macromolecule synthesis (collagen types I/III/IV, fibronectin, HA-related talk); palmitoylation improves dermal stability/permeation vs free KTTKS in permeation studies. lab
  • vs retinol (cited comparative work): Secondary/skincare-literature summaries of 3 ppm pal-KTTKS vs ~700 ppm (0.07%) retinol over ~4 months — similar roughness/deep-wrinkle improvements with better peptide tolerability (less retinoid-type inflammation). Framing is comparative cosmetic, not equivalence to prescription tretinoin. trial

Doses people talk about 18

  • DIY / raw Matrixyl 3000 complex use rate: Vendor charts commonly recommend adding ~3–8% of the commercial Matrixyl 3000 solution into finished formulas (water phase); this is complex %, not pure tri/tetrapeptide. forum
  • Matrixyl 3000 manufacturer test concentration: ~3% complex in cream, twice daily for ~2 months is the headline in-vivo protocol brands quote. Clinical summaries also reference ~2–8% commercial solution in final formulas and examples like 4% multi-peptide blends. forum
  • Matrixyl Synthe'6 use rate: Manufacturer testing/community max talk clusters around ~2% of the Synthe'6 commercial active in finished product. forum
  • “Matrixyl 10% / 20% / 25%” serums: Usually mean total branded complex load; free peptide remains dilute. Higher complex % ≠ linear free-peptide dose. forum
  • Layering order (common community sequence): Watery hydrators/toners → peptide serum → emulsions/creams → occlusives; SPF last in AM. Peptides generally sit with water-based treatments before oils. forum
  • AM vs PM split: Twice daily when tolerated; some run peptide AM + retinoid PM, or peptide on off-retinoid nights only. forum
  • Acids / low-pH clash talk: Strong AHAs/BHAs or very low-pH vitamin C same-minute layering debated — some separate by time of day to avoid irritation and theoretical peptide stability issues; others layer with wait times. Evidence is mostly practical irritation management, not hard chemistry bans. forum
  • Copper peptide co-use: Many layer Matrixyl-line peptides with GHK-Cu; others alternate AM/PM. Copper + strong L-ascorbic acid same routine is the more common “don’t smash together” warning. forum
  • Patch test: Jawline/neck several nights before full-face or eye area, especially with multi-active serums. forum
  • ppm vs % translation: 3 ppm = 0.0003%; 50 ppm = 0.005%. Community “high % Matrixyl” labels are almost never free peptide at those numbers. forum
  • The Ordinary Matrixyl 10% + HA (adjacency product math): Finished serum labeled 10% combined Matrixyl generations — community/Deciem-reported split often cited as ~8% Matrixyl 3000 + ~2% Synthe'6 in HA vehicle (not classic Pal-KTTKS). Apply a few drops 1–2× daily per brand directions. forum
  • Uncertainty: Same front-label “5% Matrixyl” can hide different complexes, different free peptide loads, and different vehicles — INCI order and raw-material COAs matter more than marketing %. forum
  • Framing: Cosmetics literature, manufacturer use rates, DIY vendor charts, and community product talk — not medical advice, not optimized clinical dosing for disease. forum
  • Classic free-peptide trial band (Pal-KTTKS): ~3 ppm (0.0003%) in finished moisturizer (Robinson 12-week split-face). trial
  • Classic free-peptide periocular band: ~0.005% palmitoyl pentapeptide-4 twice daily in profilometry-style studies (often cited as Lintner/Sederma-adjacent work). trial
  • CIR 2022 use survey (PPP-4): The highest reported leave-on concentration was 0.0012% Palmitoyl Pentapeptide-4 in eye lotions. This was a reported use concentration, not a universal safety limit or a 10% free-peptide claim. trial
  • Frequency: Once or twice daily AM and/or PM after cleanse is standard in trials and routines. trial
  • Amount (periocular trial example): Aruan protocol used ~1 finger-tip unit (~0.5 g) cream periorbital, gentle, twice daily — not a universal rule for all products. trial

How it may feel 8

  • Days 1–7: One user said The Ordinary Matrixyl—their only new product—made dry skin flaky and painful within days; a later same-author reply said they abandoned it quickly. The serum does not isolate Pal-KTTKS. forum
  • Months 3–6: Benefits often described as plateauing into maintenance; gains framed as use-dependent with SPF and barrier care. forum
  • No change by 8–12 wk: Check actual INCI (which Matrixyl?), free vs complex %, consistency, same-light photos, dehydration, and competing actives before dose-chasing another serum. forum
  • After stopping: Some keep partial smoothness from better barrier habits; others see fine lines gradually return over weeks–months — not a permanent remodel. anecdote
  • Expectations vs retinoids: Users who expect tretinoin-speed pigment/texture change often quit early; peptide wins are quieter and slower. forum
  • Weeks 2–4: Early “smoother under makeup” talk; many trials take first instrumental reads around day 28. trial
  • Weeks 4–8: Common diary/photo window for fine lines and crow’s-feet severity under twice-daily use; Aruan crow’s-feet protocol assessed at 8 weeks. trial
  • Weeks 8–12: Horizon matching Robinson-style 12-week facial photoaging endpoints and many brand “before/after” campaigns. trial

Cycles people discuss 7

  • Judgment window: ~4–12 weeks consistent use before keep/switch decisions; photo documentation recommended at fixed lighting. forum
  • No formal washout science: No established half-life-driven washout for topical Pal-KTTKS; off periods are preference, travel, barrier recovery, or product rotation. forum
  • Seasonal / barrier swaps: Some pause multi-peptide cocktails during retinization flares, procedure recovery, or winter barrier failure, then restart. forum
  • Maintenance after gains: Users who like results usually stay daily or drop to once daily rather than cycling off for months. forum
  • Restarts: Common after empty bottles, travel, or procedure downtime; long continuous use is the norm in positive logs. forum
  • Not a steroid-style PCT compound: No community “PCT,” bloodwork, or suppression narrative for topical Matrixyl. forum
  • Continuous use is the default: Treated as ongoing skincare active, not injectable on/off “cycles.” Trials run continuous twice-daily application for 4–12+ weeks. trial

Timing 7

  • No public human systemic PK/half-life: Framed as local cosmetic exposure; not characterized like an injectable peptide with plasma t½ curves. forum
  • Why daily application: Continuous local presentation assumed needed for multi-week matrix-remodeling talk; missed days slow the accumulation story more than they “clear a depot.” forum
  • AM + SPF: Peptides do not replace sunscreen; UV remains the main photoaging driver in community teaching. forum
  • Stability > blood clock: Heat, light, pH extremes, and opened-bottle oxidation of the whole formula matter more than systemic timing. Cool, opaque storage common for peptide serums. forum
  • Downstream feel: No acute neurotransmitter or stimulant cascade; if users “feel” something fast it is usually hydration film or vehicle, not peptide signaling. anecdote
  • Lag to visible change: Tonight’s application ≠ same-week collagen look — instrumental and photo changes cluster at multi-week marks. trial
  • Palmitoylation rationale: Fatty-acid conjugation is discussed for better stratum-corneum interaction and dermal stability vs free KTTKS (in-vitro permeation/stability work). lab

More on what it is 7

  • Why people use it: Long-running over-the-counter anti-wrinkle / firmness active; hyped as measurable cosmetic benefit at very low free-peptide concentrations with better tolerability than retinoids for many users. forum
  • Name trap (critical): “Matrixyl” is a brand family, not one molecule. Classic Matrixyl = palmitoyl pentapeptide-4. Matrixyl 3000 = palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7. Matrixyl Synthe'6 = palmitoyl tripeptide-38. Matrixyl Morphomics = palmitoyl tripeptide-56 acetate. Label “Matrixyl” alone is ambiguous. forum
  • % label trap: Consumer “5–10% Matrixyl” usually means % of commercial raw complex (already dilute in glycerin/water/carbomer carriers), not free Pal-KTTKS. Free active in classic trials is often in the low-ppm / ~0.0003–0.005% band. forum
  • What it is: Palmitoyl pentapeptide-4 (Pal-KTTKS = Pal-Lys-Thr-Thr-Lys-Ser): a five-amino-acid fragment related to type I collagen, palmitoylated for better skin penetration. Launched ~2000 by Sederma (now Croda Beauty) under the Matrixyl® trade name. Pre-2006 INCI name was palmitoyl pentapeptide-3. trial
  • Evidence level: Small-to-mid human cosmetic trials (including independent and brand-linked work) + in-vitro fibroblast/matrix data. Effects are generally modest, multi-week, and vehicle/moisturizer-confounded — not drug-grade remodeling claims. trial
  • Matrikine framing: Cast as a “messenger” peptide (matrikine) that can nudge fibroblasts toward extracellular-matrix renewal — collagen, elastin, fibronectin, GAG talk in manufacturer and review literature. trial
  • Not: Not a retinoid, not Botox/neuromodulator, not Argireline (expression-line peptide), not injectable BPC-157 or GHK-Cu systemic protocols, not an FDA-approved anti-aging drug. Cosmetic active, research/education framing only. trial

Stacks 10

  • HA + Matrixyl-line: Default hydration + peptide pair (e.g. The Ordinary Matrixyl 10% + HA already combines both). forum
  • Niacinamide 5–10%: Often layered same routine for barrier/tone; generally considered compatible. forum
  • Vitamin C AM / peptide PM (or reverse): Popular daylight antioxidant + evening peptide sequence to reduce same-time low-pH conflicts. forum
  • Retinoid split: Peptide AM + retinol/tret PM; or peptide on off-nights; or peptide moisturizer under mild retinol for buffer — tolerability-driven, not one fixed protocol. forum
  • Argireline / Snap-8 + Matrixyl: “Collagen signal + expression-line” cocktail for crow’s feet — Matrixyl for matrix talk, Argireline-class for dynamic lines. forum
  • Multi-Matrixyl “all gens” stacks: Some brands (e.g. Isomers-style marketing) combine classic Matrixyl + 3000 + Synthe'6 + Morphomics; ratios are proprietary and free-peptide totals remain opaque. forum
  • GHK-Cu + Matrixyl: Common dual-peptide firmness stack; copper uglies and strong acid conflicts are the main practical limits, not a hard Matrixyl ban. forum
  • Ceramide / cholesterol barrier creams: Used under or over peptides when barrier is weak so anti-aging stack doesn’t become irritation. forum
  • SPF always: Community consensus that peptides without UV protection underperform long-term. forum
  • Eye multi-peptide serums: Published example formulas stack Argireline + Matrixyl 3000 + Eyeliss-type actives for periocular endpoints — multi-active confounds apply. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 12

  • Local irritation: Mild redness, sting, dryness, or tightness — often vehicle, fragrance, preservatives, or multi-active over-stacking rather than pure Pal-KTTKS at ppm levels. forum
  • Eye migration: Periocular use is common in trials; serum drip into eyes still causes temporary burn/watery eyes — apply lightly, avoid lash line if sensitive. forum
  • Allergy / contact dermatitis outliers: True peptide allergy uncommon; fragrance, essential oils, and preservatives in “peptide serums” remain usual culprits. Patch test multi-ingredient products. forum
  • Barrier overload: Same-night strong acids + high % C + retinoid + peptide cocktail → flares wrongly blamed on “peptides.” Simplify before escalating. forum
  • Expectation mismatch / no-change logs: Lighting, dehydration, inconsistent use, or expecting neuromodulator-level freeze. anecdote
  • INCI / authenticity risk: Bargain gray serums may under-dose complexes, substitute wrong peptides, or lean on HA plump for “instant results.” Formula quality is a frequent fail point. forum
  • Brand-family confusion risk: Buying “Matrixyl” and receiving only 3000 or only Synthe'6 (or vice versa) changes which evidence base applies. Read full INCI. forum
  • % marketing deception: “10% Matrixyl” is not 10% free Pal-KTTKS; free-peptide studies worked at ppm–0.005% ranges. forum
  • Pregnancy / nursing: Not a studied drug; many users still pick peptides over retinoids in that window, but this is preference lore, not a safety trial green light. forum
  • Not a systemic safety database: Quiet side-effect threads and cosmetic use history ≠ long-term internal safety for nonstandard injectables. forum
  • Injectable research chatter: Sparse; no robust human systemic dosing literature comparable to topical cosmetics. Sterility, identity, and dose accuracy risks dominate any non-topical gray-market path. forum
  • Evidence honesty: Many headline % improvements are manufacturer-sponsored or small cosmetic panels; modest cosmetic-trial support exists (e.g. Robinson 2005, Aruan 2023) but does not equal medical treatment of aging. Robinson 2005 had Procter & Gamble-affiliated authors and should not be described as independent support. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →